The extension is set to be operational in the fourth quarter (Q4) of 2024. Credit: AptarGroup/Business Wire.

Aptar Pharma, a division of AptarGroup, has unveiled plans for a significant capacity expansion at its Congers site in New York, US.  

The extension is aimed at addressing increasing demand for proprietary drug delivery systems in North America.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The expansion includes the addition of moulds and assembly lines in clean room manufacturing settings for its Unidose Nasal Spray Systems. 

The extension is set to come online in Q4 2024.

In response to the growing demand for nasal saline solutions, the company is also installing an assembly line to expand the manufacturing of its bag-on-vale technology.  

In addition, Aptar Pharma plans to extend clean room space at the facility for its Child-Resistant Senior-Friendly closure solutions. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The added capacity will add an additional 28,500ft² building extension to bolster warehousing, clean room and manufacturing capabilities at the site. 

Aptar Pharma president Gael Touya said: “Our Aptar Pharma business in North America has shown robust growth in recent years, with increasing customer demand across all product lines.  

“This expansion is a key step in the next phase of our global expansion programme, designed to continue to meet the growing needs of our customers in the region, which will ultimately benefit patients.” 

The Congers site has been operational since 2002, initially focusing on the production of VP3 pumps, but now manufactures a diverse range of drug delivery products for nasal and injectable routes.  

Aptar Pharma’s expansion in North America is part of the company’s broader expansion plan, which includes developments in France, China and India, reinforcing its ‘local for local’ strategy.